Anti-COV19-VERS4 for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 500+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 220+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 26 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
Anti-COV19-VERS4 may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 12,000+ potential treatments.
c19early.org analyzes
220+ treatments.
We have not reviewed Anti-COV19-VERS4 in detail.
, Effective Fragrance Molecules and Essential Oils: A Potential Relief for COVID-19, Natural Product Communications, doi:10.1177/1934578X261487547
Objectives Essential oils and their chemical constituents are recognized for their antimicrobial properties against many infections. In this study, some molecules of essential oils are identified as potentially effective on the MPro of SARS-CoV-2 and as a BRD2 inhibitors. These essential oils were combined in an optimum formulation as (Anti-COV19-VERS4). This study evaluates the role of Anti-COV19-VERS4, in preventing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) contagiousness and its secondary effects on infected tissues by in-vivo experiments. Methods Anti-COV19-VERS4 is formulated based on molecular docking studies. Following cytotoxic and antiviral dose determination, SARS-CoV-2 infected transgenic mice were treated with Anti-COV19-VERS4 spray. RT-qPCR was used to detect viral load and histopathologic analysis was performed. The experiment was terminated on the days of 5 and 6 when SARS-CoV-2 infection peaked. RT-qPCR was used to detect viral load and histopathologic analysis was performed. Two-way ANOVA and Student’s t -tests were used for statistical analysis. Results Cytotoxicity and neutralization assays revealed that the most effective dilution of Anti-COV19-VERS4 showing cytopathic effect (CPE) was 1/2600 and the 24-hour CC50 dose was 0.0154 mg/L. During in-vivo trials, 3 out of 14 mice in the control group died due to infection. The virus load of the Anti-COV19-VERS4 spray group on day 6 decreased compared to the control group. Moreover, lung injury scores for the Anti-COV19-VERS4 spray group were significantly lower than the control group on the 6 th day (p<0.05). This study demonstrates that Anti-COV19-VERS4 may be useful for preventing the contagiousness of SARS-CoV-2 and relieving lung injury. Conclusion Anti-COV19-VERS4 may be helpful as a cost-effective and efficacious adjunctive therapy for SARS-CoV-2.